OP36 Real-world evidence on comparative effectiveness of Ustekinumab vs anti-TNF in Crohn’s disease with propensity score adjustment: two-year maintenance phase results from the prospective observational RUN-CD study

Bokemeyer, B.(1,2,3)*;Plachta-Danielzik, S.(3);Deppe, H.(4);Mohl, W.(5);Teich, N.(6);Hoffstadt, M.(7);Schweitzer, A.(8);von der Ohe, M.(9);Gauss, A.(10);Atreya, R.(11);Krause, T.(12);Blumenstein, I.(13);Fajardo Salmon, S.(3);Hartmann, P.(4);Gilman, E.(3);Schreiber, S.(3,14);

(1)Prof. Dr. Bernd Bokemeyer, Interdisciplinary Crohn Colitis Centre Minden, Minden, Germany;(2)University Hospital Schleswig-Holstein- Campus Kiel, Clinic for General Internal Medicine I, Kiel, Germany;(3)Competence Network IBD, Study Department, Kiel, Germany;(4)Gastroenterology Practice Minden, Gastroenterology, Minden, Germany;(5)Centre for Gastroenterology Saar MVZ, Gastroenterology, Saarbrücken, Germany;(6)Gastroenterology Practice Leipzig, Gastroenterology, Leipzig, Germany;(7)Gastroenterology Practice Iserlohn, Gastroenterology, Iserlohn, Germany;(8)Gastroenterology Practice Münster, Gastroenterology, Münster, Germany;(9)Gastroenterology Practice Herne, Gastroenterology, Herne, Germany;(10)University Hospital Heidelberg, Department Internal Medicine IV - Gastroenterology Clinic, Heidelberg, Germany;(11)Friedrich-Alexander-University Erlangen-Nürnberg, Medical Clinic 1, Erlangen, Germany;(12)Gastroenterology Practice Kassel, Gastroenterology, Kassel, Germany;(13)Johann Wolfgang Goethe University Clinic Frankfurt, Department of Gastroenterology and Clinical Nutrition, Frankfurt, Germany;(14)University Hospital Schleswig-Holstein Campus Kiel, Clinic of General Internal Medicine I, Kiel, Germany;